Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.
Jae-Seung Yun,Seung Hyun Ko +1 more
Reads0
Chats0
TLDR
In this article, the authors discuss the current epidemiologic trends of CVD in Type 2 diabetes mellitus and the risk factors linking T2DM to CVD, including genetic contribution, hypoglycaemia, and insulin resistance, and proper care strategies, including lifestyle and therapeutic approaches.Abstract:
With the advances in diabetes care, the trend of incident cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) has been decreasing over past decades. However, given that CVD is still a major cause of death in patients with diabetes and that the risk of CVD in patients with T2DM is more than twice that in those without DM, there are still considerable challenges to the prevention of CVD in diabetes. Accordingly, there have been several research efforts to decrease cardiovascular (CV) risk in T2DM. Large-scale genome-wide association studies (GWAS) and clinical cohort studies have investigated the effects of factors, such as genetic determinants, hypoglycaemia, and insulin resistance, on CVD and can account for the unexplained CV risk in T2DM. Lifestyle modification is a widely accepted cornerstone method to prevent CVD as the first-line strategy in T2DM. Recent reports from large CV outcome trials have proven the positive CV effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with high CVD risk. Overall, current practice guidelines for the management of CVD in T2DM are moving from a glucocentric strategy to a more individualised patient-centred approach. This review will discuss the current epidemiologic trends of CVD in T2DM and the risk factors linking T2DM to CVD, including genetic contribution, hypoglycaemia, and insulin resistance, and proper care strategies, including lifestyle and therapeutic approaches.read more
Citations
More filters
Journal ArticleDOI
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
TL;DR: In this article , the important issues affecting the choice of antidiabetic agents and lipid, blood pressure, and antiplatelet treatments considering the cardiovascular status of the patient are discussed.
Journal ArticleDOI
Pharmacotherapy of type 2 diabetes: An update and future directions.
Antea DeMarsilis,Niyoti Reddy,Chrysoula Boutari,Andreas Filippaios,Elliot Sternthal,Niki Katsiki,Christos S. Mantzoros +6 more
TL;DR: In this paper , the authors provide an updated summary of the pharmacotherapeutic approach to Type 2 diabetes (T2D) and outline an up-to-date treatment approach that starts with identification of an individualized goal for glycemic control then selection, initiation, and further intensification of a personalized therapeutic plan for T2D.
Journal ArticleDOI
2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.
Samuel Seidu,Xavier Cos,Stephen Brunton,Stewart B. Harris,Stefan Jansson,Manel Mata-Cases,A. M. J. Neijens,Pinar Topsever,Kamlesh Khunti +8 more
TL;DR: In this paper , a simple and patient-centred clinical decision-making model with practical treatment recommendations that can be widely implemented by primary care clinicians worldwide through shared-decision conversations with their patients is presented.
Journal ArticleDOI
Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and Type 2 diabetes in patients with coronary heart disease: a RCSCD-TCM study in China
Tong Yang,Yi-jing Liu,Lin Li,Yanchao Zheng,Yang Wang,Jinyu Su,Rongrong Yang,M. Luo,Chunquan Yu +8 more
TL;DR: In this article , the association of non-traditional lipid markers with pre-DM and Type 2 diabetes mellitus (T2DM) was investigated in coronary heart disease (CHD) patients.
Journal ArticleDOI
Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review.
Alexandros-Leonidas D Liarakos,Anastasios Tentolouris,Alexander Kokkinos,Ioanna Eleftheriadou,Nicholas Tentolouris +4 more
TL;DR: In this paper , the impact of Glucagon-like peptide 1 (GLP-1) receptor agonists on peripheral arterial disease (PAD) among people with type 2 diabetes mellitus was examined.
References
More filters
Journal ArticleDOI
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman,Christoph Wanner,John M. Lachin,David Fitchett,Erich Bluhmki,Stefan Hantel,Michaela Mattheus,Theresa Devins,Odd Erik Johansen,Hans-Juergen Woerle,Uli C. Broedl,Silvio E. Inzucchi +11 more
TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.
Journal ArticleDOI
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William C. Duckworth,Carlos Abraira,Thomas E. Moritz,Domenic J. Reda,Nicholas V. Emanuele,Peter D. Reaven,Franklin J. Zieve,Jennifer B. Marks,Stephen N. Davis,Rodney A. Hayward,Stuart R. Warren,Steven Goldman,Madeline McCarren,Mary Ellen Vitek,William G. Henderson,Grant D. Huang +15 more
TL;DR: Intensive glucose control in patients with poorly controlled type 2 diabetes had no significant effect on the rates of major cardiovascular events, death, or microvascular complications with the exception of progression of albuminuria.